Patient disposition. Enrollment: May 2011 to January 2013. (1) Forty-four patients enrolled and received single-agent carfilzomib 20/56 mg/m2 with (2) 42 response evaluable and (3) 35 evaluable per protocol. (4) Patients who achieved less than PR within 2 cycles of single-agent carfilzomib could have (5) low-dose dexamethasone (20 mg) added to their regimen and continued treatment until POD or intolerable toxicity. (6) Patients who achieved at least PR within 2 cycles continued single-agent carfilzomib until POD, at which time they had the option of discontinuing treatment or (7) modifying the carfilzomib regimen with the addition of low-dose dexamethasone to potentially overcome resistance and prolong therapy. Data cutoff: June 2013. CFZ, carfilzomib; dex, dexamethasone; CFZ + dex, CFZ in combination with low-dose dex.
